# A Study Using Real-world Data to Examine Outcomes in Children and Adults Who Develop a Blood Clotting Disorder Called Thrombotic Microangiopathy (TMA) After Undergoing a Hematopoietic Stem Cell Transplant (HSCT).

> **NCT07732361** · — · COMPLETED · sponsor: **Alexion Pharmaceuticals, Inc.** · enrollment: 307 (actual)

## Conditions studied

- Thrombotic Microangiopathy
- Hematopoietic Stem Cell Transplant

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT07732361
- **Lead sponsor:** Alexion Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2025-01-22
- **Primary completion:** 2026-03-31
- **Final completion:** 2026-03-31
- **Target enrollment:** 307 (ACTUAL)
- **Last updated:** 2026-07-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07732361

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07732361, "A Study Using Real-world Data to Examine Outcomes in Children and Adults Who Develop a Blood Clotting Disorder Called Thrombotic Microangiopathy (TMA) After Undergoing a Hematopoietic Stem Cell Transplant (HSCT).". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07732361. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*